nafronyl has been researched along with Obesity in 1 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A retrospective analysis was performed on all five published clinical trials in which naftidrofuryl was given at a dosage of 600 mg daily." | 2.67 | Naftidrofuryl in intermittent claudication: a retrospective analysis. ( Brown, TM; Comte, S; Gamand, S; Lehert, P, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lehert, P | 1 |
| Comte, S | 1 |
| Gamand, S | 1 |
| Brown, TM | 1 |
1 trial available for nafronyl and Obesity
| Article | Year |
|---|---|
Naftidrofuryl in intermittent claudication: a retrospective analysis.
Topics: Cardiovascular Diseases; Exercise; Female; Humans; Intermittent Claudication; Male; Middle Aged; Naf | 1994 |